ABG
SLNO

Ally Bridge Group’s Soleno Therapeutics SLNO Stock Holding History

Ally Bridge Group’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.7M Buy
+200,000
New +$7.84M 5.41% 4

Other funds holding SLNO

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
KCM
Khrom Capital Management Miami Beach, Florida $1.09B AUM 14.82% 1-Year Est. Return

Ally Bridge Group's SLNO Position: Q1 2026 in Review

Ally Bridge Group increased its Soleno Therapeutics (SLNO) stake by 19% in Q1 2026, buying an estimated $1.25M and bringing the position to 200,000 shares worth $6.7M. The position accounts for 5.41% of the portfolio, ranked #3.

Ally Bridge Group first reported a position in SLNO in Q4 2023 and has held it in 9 quarters since. The position peaked at $20.4M in Q3 2025. 225 funds tracked by Wall St. Rank hold SLNO as of Q1 2026.

  • Ally Bridge Group held 200,000 shares of Soleno Therapeutics worth $6.7M as of Q1 2026.
  • Ally Bridge Group bought 31,971 Soleno Therapeutics shares in Q1 2026, an estimated $1.25M.
  • Soleno Therapeutics made up 5.41% of Ally Bridge Group's portfolio in Q1 2026, its #3 holding.
  • Ally Bridge Group first reported a position in Soleno Therapeutics in Q4 2023 and has held it in 9 quarters since.
  • Ally Bridge Group's Soleno Therapeutics position peaked at $20.4M in Q3 2025.
  • 225 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q1 2026.

Based on Ally Bridge Group's 13F filing for Q1 2026, filed 18 May 2026.